VBIO Valion Bio, Inc. Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 52
- List Date
- 2021-11-11
- CIK
- 0001787740
- Next Earnings
- 2026-11-13
- Headquarters
- San Antonio, TX
- Homepage
- https://www.tivichealth.com
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -- | -- |
| Mar | -- | -- |
| Apr | -2.99% | -2.99% |
| May | -16.74% | -16.74% |
| Jun | -25.04% | -25.04% |
| Jul | -40.21% | -40.21% |
| Aug | -54.81% | -54.81% |
| Sep | -8.79% | -8.79% |
| Oct | -66.53%* | -66.53% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | -95.01% | -95.01% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
VBIO Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 125
Period: 252 trading days
Negative beta - stock moves opposite to market
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $39K | #6069 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
VBIO Institutional Ownership (13F)
Latest filings — 2026-09-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
VBIO Insider Trading (Form 4)
Latest: 2026-09-24| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Dean Zikria | Interim CEO | Grant (A) | +50,000 RSU | — | EDGAR | |
| 2026-09-24 | Lisa G Wolf | COO & CFO | Mixed | +2 | $2.12 | -$4 | EDGAR |
| 2026-06-18 | Lisa G Wolf | Chief Financial Officer | Exer (M) | +92 | — | EDGAR | |
| 2026-05-20 | Michael K Handley | Chief Executive Officer | Exer (M) | +2,206 | — | EDGAR | |
| 2026-05-04 | Melinda Lackey | General Counsel & SVP of Legal | Grant (A) | +45,000 opt | — | EDGAR |
VBIO Insider Holdings
2 insiders · @ $0.84| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Michael K Handley | Chief Executive Officer | 441 | $370 | $0 | 1 | 2026-05-20 |
| 2 | Lisa G Wolf | COO & CFO | 27 | $23 | $0 | 2 | 2026-09-24 |
VBIO Board & Officers
As of SEC filings through Sep 24, 2026Directors 6
- Dean Zikria · since Nov 10, 2021
- Sheryle Bolton · since Nov 10, 2021
- Christina Rizopoulos Valauri · since Jul 1, 2024
- Michael K Handley · listed since May 2026
- Jared David Malbin · since Aug 27, 2026
- Thomas Jensen · since Aug 27, 2026
Officers 4
- Dean Zikria · Interim CEO · listed since Sep 2026
- Lisa G Wolf · Chief Financial Officer · listed since Aug 2025
- Michael K Handley · Chief Operating Officer · since Feb 18, 2025
- Melinda Lackey · General Counsel & SVP of Legal · since May 1, 2026
Changes in the last 10 years (31)
| Sep 24, 2026 | Dean Zikria first listed as Interim CEO in an SEC filing |
| Aug 27, 2026 | Thomas Jensen became a director |
| Aug 27, 2026 | Jared David Malbin became a director |
| May 20, 2026 | Michael K Handley first listed as a director in an SEC filing |
| May 1, 2026 | Melinda Lackey became General Counsel & SVP of Legal |
| Mar 2, 2026 | The company announced the departure of Jennifer Ernst from the board in an SEC filing |
| Mar 2, 2026 | The company announced the departure of Jennifer Ernst as Chief Executive Officer in an SEC filing |
| Aug 8, 2025 | Lisa G Wolf listed as Chief Financial Officer (previously Interim CFO) in SEC filings |
| Jun 30, 2025 | The company announced the departure of Blake Gurfein as Chief Scientific Officer in an SEC filing |
| Feb 18, 2025 | Michael K Handley became Chief Operating Officer |
| Oct 1, 2024 | Lisa G Wolf became Interim CFO |
| Oct 1, 2024 | Kimberly Ann Bambach left as Interim CFO, per their own SEC filing |
| Sep 30, 2024 | Karen Drexler left the board, per their own SEC filing |
| Jul 1, 2024 | Christina Rizopoulos Valauri became a director |
| Jan 22, 2024 | The company announced the departure of Ryan Sabia as Chief Operating Officer in an SEC filing |
| May 10, 2023 | Jennifer Ernst no longer listed as a 10% owner in SEC filings |
| Apr 28, 2023 | The company announced the departure of Veronica Cai as Chief Financial Officer in an SEC filing |
| Apr 28, 2023 | Kimberly Ann Bambach became Interim CFO |
| Apr 1, 2022 | Veronica Cai became Chief Financial Officer |
| Apr 1, 2022 | The company announced the departure of Briana Benz as Chief Financial Officer in an SEC filing |
| Feb 8, 2022 | Ryan Sabia listed as Chief Operating Officer (previously VP of Sales and Operations) in SEC filings |
| Nov 10, 2021 | Sheryle Bolton became a director |
| Nov 10, 2021 | Ryan Sabia became VP of Sales and Operations |
| Nov 10, 2021 | Karen Drexler became a director |
| Nov 10, 2021 | John Claude became a 10% owner |
| Nov 10, 2021 | Jennifer Ernst became a director |
| Nov 10, 2021 | Jennifer Ernst became a 10% owner |
| Nov 10, 2021 | Jennifer Ernst became Chief Executive Officer |
| Nov 10, 2021 | Dean Zikria became a director |
| Nov 10, 2021 | Briana Benz became Chief Financial Officer |
| Nov 10, 2021 | Blake Gurfein became Chief Scientific Officer |
- Prev
- 1
Not reported recently (1)
- John Claude · Last reported as a 10% owner in an SEC filing dated Nov 10, 2021
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.